Susan Warner | Jul 27, 2003 | 7 min read
In a move designed to speed approval of new biotech products, the US Food & Drug Administration has transferred oversight for many new biotech therapies from its office that reviews biologics to the one that approves traditional drugs. Biotech and pharmaceutical companies had been pushing for the change for years, because it's generally believed that companies can more easily get regulatory clearance from the drug review section of the agency. This change became a reality with the arriva